Gary L. Wright
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Gary L. Wright has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
Chuan-Yuan Li
Department of Pharmaceutical Sciences, Medical University of South Carolina, Charleston, South Carolina
1 shared publicationCraig Cano Beeson
Department of Pharmaceutical Sciences, Medical University of South Carolina, Charleston, South Carolina
1 shared publicationH. Kasiganesan
Department of Pharmaceutical Sciences, Medical University of South Carolina, Charleston, SC 29425, USA
1 shared publicationJason Guichard
Department of Pharmaceutical Sciences, Medical University of South Carolina, Charleston, South Carolina
1 shared publicationRobin Muise-Helmericks
Department of Pharmaceutical Sciences, Medical University of South Carolina, Charleston, South Carolina
1 shared publicationV. Sridharan
Department of Pharmaceutical Sciences, Medical University of South Carolina, Charleston, SC, USA
1 shared publication
Latest Publications
- 1 July 2008
- Published by American Physiological Society in American Journal of Physiology-Cell Physiology
- Vol. 295 (1) , C29-C37
O2-sensing signal cascade: clamping of O2 respiration, reduced ATP utilization, and inducible fumarate respiration
These studies explore the consequences of activating the prolyl hydroxylase (PHD) O2-sensing pathway in spontaneously twitching neonatal cardiomyocytes. Full activation of the PHD pathway was achieved using the broad-spectrum PHD inhibitor (PHI) dimethyloxaloylglycine (DMOG). PHI treatment of cardiomyocytes caused an 85% decrease in O2 consumption and a 300% increase in lactic acid production under basal conditions. This indicates a ∼75% decrease in ATP turnover rate, inasmuch as the increased ATP generation by glycolysis is inadequate to compensate for the lower respiration. To determine the extent to which decreased ATP turnover underlies the suppressed O2 consumption, mitochondria were uncoupled with 2,4-dinitrophenol. We were surprised to find that 2,4-dinitrophenol failed to increase O2 consumption by PHI-treated cells, indicating that electron transport chain activity, rather than ATP turnover rate, limits respiration in PHI-treated cardiomyocytes. Silencing of hypoxia-inducible factor-1α (HIF-1α) expression restored the ability of uncoupled PHI-treated myocytes to increase O2 consumption; however, basal O2 uptake rates remained low because of the unabated suppression of cellular ATP consumption. Thus it appears that respiration is actively “clamped” through an HIF-dependent mechanism, whereas HIF-independent mechanisms are responsible for downregulation of ATP consumption. In addition, we find that PHD pathway activation enables mitochondria to utilize fumarate as a terminal electron acceptor when cytochrome c oxidase is inactive. The source of fumarate for this unusual respiration is derived from aspartate via the purine nucleotide cycle. In sum, these studies show that the O2-sensing pathway is sufficient to actively “clamp” O2 consumption and independently suppress cellular ATP consumption. The PHD pathway also enables the mitochondria to utilize fumarate for respiration.
- 1 July 2008
- Published by American Physiological Society in American Journal of Physiology-Cell Physiology
- Vol. 295 (1) , C29-C37
O2-sensing signal cascade: clamping of O2 respiration, reduced ATP utilization, and inducible fumarate respiration
These studies explore the consequences of activating the prolyl hydroxylase (PHD) O2-sensing pathway in spontaneously twitching neonatal cardiomyocytes. Full activation of the PHD pathway was achieved using the broad-spectrum PHD inhibitor (PHI) dimethyloxaloylglycine (DMOG). PHI treatment of cardiomyocytes caused an 85% decrease in O2 consumption and a 300% increase in lactic acid production under basal conditions. This indicates a ∼75% decrease in ATP turnover rate, inasmuch as the increased ATP generation by glycolysis is inadequate to compensate for the lower respiration. To determine the extent to which decreased ATP turnover underlies the suppressed O2 consumption, mitochondria were uncoupled with 2,4-dinitrophenol. We were surprised to find that 2,4-dinitrophenol failed to increase O2 consumption by PHI-treated cells, indicating that electron transport chain activity, rather than ATP turnover rate, limits respiration in PHI-treated cardiomyocytes. Silencing of hypoxia-inducible factor-1α (HIF-1α) expression restored the ability of uncoupled PHI-treated myocytes to increase O2 consumption; however, basal O2 uptake rates remained low because of the unabated suppression of cellular ATP consumption. Thus it appears that respiration is actively “clamped” through an HIF-dependent mechanism, whereas HIF-independent mechanisms are responsible for downregulation of ATP consumption. In addition, we find that PHD pathway activation enables mitochondria to utilize fumarate as a terminal electron acceptor when cytochrome c oxidase is inactive. The source of fumarate for this unusual respiration is derived from aspartate via the purine nucleotide cycle. In sum, these studies show that the O2-sensing pathway is sufficient to actively “clamp” O2 consumption and independently suppress cellular ATP consumption. The PHD pathway also enables the mitochondria to utilize fumarate for respiration.
- 5 April 2007
- Published by Wiley in Acta Physiologica
- Vol. 190 (2) , 163-169
Prolyl hydroxylase inhibitor treatment confers whole‐animal hypoxia tolerance
Aim: Recently a family of O2‐dependent prolyl hydroxylase domain‐containing enzymes (PHD) has been identified as a cellular oxygen‐sensing mechanism. Reduced prolyl hydroxylase activity initiates a signalling cascade that includes the accumulation, as well as the activation, of hypoxia‐inducible factor (HIF‐1α). In turn the transcription factor HIF‐1α, and other targets of the PHD, elicit a myriad of incompletely understood cellular responses. In these studies we have tested: (1) whether a small‐molecule prolyl hydroxylase inhibitor (PHI) can effectively activate the oxygen‐sensing pathway when administered systemically to mice, and (2) whether the activation of the PHD signalling pathway at the cellular level results in whole‐animal hypoxic tolerance.Methods: Mice received daily injections of the PHI, ethyl‐3,4 dihydroxybenzoate (EDHB, 100–250 mg kg−1) or vehicle. Tissue levels of HIF‐1α and the serum levels of the HIF‐inducible gene, erythropoietin (EPO), were measured to evaluate PHD‐pathway activation. To evaluate hypoxic tolerance, the endurance and survival ability of these animals was tested in sublethal (8% O2) and lethal hypoxia (5% O2) respectively.Results: Systemic treatment of mice with the PHD inhibitor, EDHB, leads to elevated levels of HIF‐1α in liver and HIF‐inducible EPO in serum, indicating activation of the cellular oxygen‐sensing pathway. Animals treated with EDHB display significantly increased viability and enhanced exercise performance in hypoxia.Conclusion: These results demonstrate a novel pharmacological strategy to induce hypoxic tolerance and are the first to demonstrate that the activation of the PHD oxygen‐sensing pathway at the cellular level is sufficient to produce a hypoxic‐tolerant phenotype at the physiological level of the whole animal.
- 5 April 2007
- Published by Wiley in Acta Physiologica
- Vol. 190 (2) , 163-169
Prolyl hydroxylase inhibitor treatment confers whole‐animal hypoxia tolerance
Aim: Recently a family of O2‐dependent prolyl hydroxylase domain‐containing enzymes (PHD) has been identified as a cellular oxygen‐sensing mechanism. Reduced prolyl hydroxylase activity initiates a signalling cascade that includes the accumulation, as well as the activation, of hypoxia‐inducible factor (HIF‐1α). In turn the transcription factor HIF‐1α, and other targets of the PHD, elicit a myriad of incompletely understood cellular responses. In these studies we have tested: (1) whether a small‐molecule prolyl hydroxylase inhibitor (PHI) can effectively activate the oxygen‐sensing pathway when administered systemically to mice, and (2) whether the activation of the PHD signalling pathway at the cellular level results in whole‐animal hypoxic tolerance.Methods: Mice received daily injections of the PHI, ethyl‐3,4 dihydroxybenzoate (EDHB, 100–250 mg kg−1) or vehicle. Tissue levels of HIF‐1α and the serum levels of the HIF‐inducible gene, erythropoietin (EPO), were measured to evaluate PHD‐pathway activation. To evaluate hypoxic tolerance, the endurance and survival ability of these animals was tested in sublethal (8% O2) and lethal hypoxia (5% O2) respectively.Results: Systemic treatment of mice with the PHD inhibitor, EDHB, leads to elevated levels of HIF‐1α in liver and HIF‐inducible EPO in serum, indicating activation of the cellular oxygen‐sensing pathway. Animals treated with EDHB display significantly increased viability and enhanced exercise performance in hypoxia.Conclusion: These results demonstrate a novel pharmacological strategy to induce hypoxic tolerance and are the first to demonstrate that the activation of the PHD oxygen‐sensing pathway at the cellular level is sufficient to produce a hypoxic‐tolerant phenotype at the physiological level of the whole animal.